We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

57 hedge funds and large institutions have $83.2M invested in ImmunityBio in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 11

118% more call options, than puts

Call options by funds: $480K | Put options by funds: $220K

0.95% more ownership

Funds ownership: 18.16% → 19.11% (+0.95%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

2% less funds holding

Funds holding: 58 → 57 (-1)

27% less capital invested

Capital invested by funds: $113M → $83.2M (-$30.1M)

Holders
57
Holders Change
-1
Holders Change %
-1.72%
% of All Funds
1.42%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
24
Reduced
11
Closed
6
Calls
$480K
Puts
$220K
Net Calls
+$260K
Net Calls Change
+$809K

Top Buyers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
+$765K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$677K
3
Renaissance Technologies
Renaissance Technologies
New York
+$614K
4
HK
Horizon Kinetics
New York
+$430K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$331K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$792K
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$632K
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$380K
4
PPA
Parametric Portfolio Associates
Washington
-$197K
5
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
-$180K
Name Holding Trade Value Shares
Change 		Change in
Stake
WCM
1
Wildcat Capital Management
New York
$18.6M – – –
BlackRock
2
BlackRock
New York
$15.3M +$259K +42,061 +2%
Capital Research Global Investors
3
Capital Research Global Investors
California
$14.6M – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$8.95M -$632K -102,601 -6%
Vanguard Group
5
Vanguard Group
Pennsylvania
$8.75M +$677K +109,914 +7%
State Street
6
State Street
Massachusetts
$1.95M +$94.5K +15,331 +4%
Northern Trust
7
Northern Trust
Illinois
$1.77M +$112K +18,173 +6%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$1.51M -$96.5K -15,657 -5%
AG
9
Artal Group
Luxembourg
$1.23M – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$1.04M +$614K +99,700 +112%
VIA
11
Vident Investment Advisory
Georgia
$1.02M +$34.9K +5,661 +3%
Invesco
12
Invesco
Georgia
$737K +$765K +124,061 +1,183%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$642K -$31.1K -5,044 -4%
Charles Schwab
14
Charles Schwab
California
$604K +$30.1K +4,891 +5%
TCIM
15
TIAA CREF Investment Management
New York
$453K +$8.25K +1,339 +2%
AA
16
ALPS Advisors
Colorado
$429K +$25.1K +4,081 +6%
HK
17
Horizon Kinetics
New York
$382K +$430K +69,698 New
Morgan Stanley
18
Morgan Stanley
New York
$341K +$153K +24,886 +67%
TA
19
Teachers Advisors
New York
$307K – – –
AllianceBernstein
20
AllianceBernstein
Tennessee
$301K – – –
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$294K +$331K +53,668 New
DekaBank Deutsche Girozentrale
22
DekaBank Deutsche Girozentrale
Germany
$273K – – –
SG Americas Securities
23
SG Americas Securities
New York
$270K +$218K +35,424 +254%
California State Teachers Retirement System (CalSTRS)
24
California State Teachers Retirement System (CalSTRS)
California
$261K -$40.4K -6,550 -12%
ProShare Advisors
25
ProShare Advisors
Maryland
$257K +$12.2K +1,975 +4%
1
2 3

IBRX Hedge Fund Activity: Q3 2017 in Review

57 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2017, worth a combined $83.2M — down 27% from $113M a quarter earlier.

Fund positioning in IBRX was balanced in Q3 2017: 6 funds opened new positions, 6 closed out, 24 added to existing stakes and 11 trimmed.

The largest buyer was Invesco, adding an estimated $765K. The largest seller was JP Morgan Chase, cutting an estimated $792K.

  • 57 institutional investors held ImmunityBio (IBRX) as of Q3 2017, down from 58 in Q2 2017.
  • Funds reported $83.2M of ImmunityBio stock for Q3 2017, down 27% quarter-over-quarter.
  • 6 funds opened new ImmunityBio positions in Q3 2017 and 6 closed out, a net change of 0 holders.
  • The largest ImmunityBio buyer in Q3 2017 was Invesco, an estimated $765K added.
  • The largest ImmunityBio seller in Q3 2017 was JP Morgan Chase, an estimated $792K sold.

Based on aggregated 13F filings for Q3 2017.